Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.53
-0.0600-2.32%
Post-market: 2.550.0200+0.79%19:59 EDT
Volume:6.04M
Turnover:15.37M
Market Cap:272.58M
PE:-0.97
High:2.70
Open:2.58
Low:2.50
Close:2.59
Loading ...

Rocket Pharmaceuticals Cut to Hold From Buy by Needham

Dow Jones
·
27 May

J.P. Morgan Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
27 May

Needham downgrades Rocket Pharmaceuticals (RCKT) to a Hold

TIPRANKS
·
27 May

Rocket Pharmaceuticals Inc : Wedbush Cuts Target Price to $16 From $32

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush

TIPRANKS
·
27 May

Rocket Pharmaceuticals Shares Down 56.5% After Patient Dies in Mid-Stage Gene Therapy Trial; FDA Puts Clinical Hold

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Exec Says the Patient Who Experienced the Serious Adverse Event Was Treated in Early May - Conf Call

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Shares Down as Trial Patient Dies of Complications

Dow Jones
·
27 May

Rocket Pharmaceuticals announces serious adverse event in RP-A501 trial

TIPRANKS
·
27 May

Rocket Pharmaceuticals Shares Down 52% Premarket After Patient Dies in Mid-Stage Gene Therapy Trial; FDA Puts Clinical Hold

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of Rp-a501 for Danon Disease

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - in Active Dialogue With FDA After Sae in Rp-a501 Trial

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Expects Resources to Fund Operations Into 2027

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Patient in Rp-a501 Phase 2 Trial Experiences Serious Adverse Event

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Unable to Provide Guidance on Anticipated Timing for Completion of Phase 2 Trial

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - FDA Places Clinical Hold on Rp-a501 Trial After Sae

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals CFO John Militello Reports Disposal of Common Shares

Reuters
·
23 May

Rocket Pharmaceuticals' General Counsel Martin Wilson Reports Disposal of Common Shares

Reuters
·
21 May

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer, Reports Disposal of Common Shares of Rocket Pharmaceuticals Inc

Reuters
·
21 May

CEO Gaurav Shah Reports Disposal of Common Shares of Rocket Pharmaceuticals Inc

Reuters
·
21 May